IONIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.59 USD | -0.60% |
|
+2.24% | -17.79% |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 10 | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,497 | 7,906 | 4,297 | 5,365 | 7,258 | 6,066 | - | - |
| Enterprise Value (EV) 1 | 8,602 | 8,047 | 4,649 | 4,561 | 6,157 | 5,955 | 6,284 | 6,391 |
| P/E ratio | 29 x | -17.5 x | -152 x | -19.9 x | -19.8 x | -10.5 x | -12.2 x | -22.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.57 x | 10.8 x | 5.3 x | 9.14 x | 9.21 x | 9.72 x | 7.92 x | 5.49 x |
| EV / Revenue | 7.66 x | 11 x | 5.74 x | 7.77 x | 7.81 x | 9.54 x | 8.2 x | 5.79 x |
| EV / EBITDA | 22.7 x | -50.7 x | 35.6 x | -11.5 x | -18 x | -11.3 x | -11.9 x | -23.8 x |
| EV / FCF | 27.3 x | 10.4 x | 247 x | -15.7 x | -18.6 x | -11.9 x | -13.4 x | -26.1 x |
| FCF Yield | 3.66% | 9.59% | 0.41% | -6.36% | -5.38% | -8.39% | -7.44% | -3.82% |
| Price to Book | 5.12 x | 9.39 x | 5.57 x | 9.37 x | 18.9 x | -115 x | -11.4 x | -9.76 x |
| Nbr of stocks (in thousands) | 140,663 | 139,823 | 141,210 | 142,050 | 143,472 | 145,846 | - | - |
| Reference price 2 | 60.41 | 56.54 | 30.43 | 37.77 | 50.59 | 41.59 | 41.59 | 41.59 |
| Announcement Date | 2/26/20 | 2/24/21 | 2/24/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,123 | 729 | 810 | 587 | 788 | 624.1 | 765.9 | 1,105 |
| EBITDA 1 | 378.4 | -158.7 | 130.5 | -395.9 | -342.7 | -526.7 | -528.3 | -268 |
| EBIT 1 | 366 | -172 | -30 | -411 | -353 | -577.5 | -489.7 | -275.4 |
| Operating Margin | 32.59% | -23.59% | -3.7% | -70.02% | -44.8% | -92.54% | -63.94% | -24.94% |
| Earnings before Tax (EBT) 1 | 347 | -170 | -30 | -258 | -334 | -600.6 | -535.6 | -318.4 |
| Net income 1 | 294 | -451 | -29 | -270 | -366 | -572.4 | -503.6 | -281.4 |
| Net margin | 26.18% | -61.87% | -3.58% | -46% | -46.45% | -91.71% | -65.76% | -25.48% |
| EPS 2 | 2.080 | -3.230 | -0.2000 | -1.900 | -2.560 | -3.968 | -3.404 | -1.886 |
| Free Cash Flow 1 | 314.8 | 772 | 18.84 | -290.1 | -331.3 | -499.5 | -467.4 | -244.4 |
| FCF margin | 28.03% | 105.9% | 2.33% | -49.42% | -42.05% | -80.03% | -61.03% | -22.13% |
| FCF Conversion (EBITDA) | 83.19% | - | 14.44% | - | - | - | - | - |
| FCF Conversion (Net income) | 107.08% | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/24/21 | 2/24/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 133 | 440 | 142 | 134 | 160 | 152 | 131 | 188 | 144 | 325 | 141.7 | 144.6 | 164 | 173.2 | 148.6 |
| EBITDA 1 | -82.14 | 247.8 | -53.8 | -81.73 | -55.34 | -205 | -111.4 | - | -140.7 | -3.456 | -152.1 | -155.2 | -97.15 | -104.3 | - |
| EBIT 1 | -86 | 221 | -57 | -86 | -59 | -208 | -114 | -91 | -143 | -6 | -151.8 | -159.2 | -143.9 | -149.5 | -169.5 |
| Operating Margin | -64.66% | 50.23% | -40.14% | -64.18% | -36.88% | -136.84% | -87.02% | -48.4% | -99.31% | -1.85% | -107.15% | -110.07% | -87.74% | -86.3% | -114.08% |
| Earnings before Tax (EBT) 1 | -84 | 225 | -64 | -103 | -47 | -44 | -113 | -77 | -141 | -3 | -152.8 | -163.3 | -146.6 | -147 | -186.1 |
| Net income 1 | -82 | 225 | -65 | -105 | -47 | -52 | -124 | -85 | -147 | -9 | -150.7 | -159.8 | -145.7 | -146.9 | -186.8 |
| Net margin | -61.65% | 51.14% | -45.77% | -78.36% | -29.38% | -34.21% | -94.66% | -45.21% | -102.08% | -2.77% | -106.36% | -110.49% | -88.81% | -84.81% | -125.73% |
| EPS 2 | -0.5800 | 1.410 | -0.4600 | -0.7400 | -0.3300 | -0.3700 | -0.8700 | -0.6000 | -1.030 | -0.0600 | -1.032 | -1.055 | -0.9896 | -1.032 | -1.267 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/24/22 | 5/4/22 | 8/9/22 | 11/9/22 | 2/22/23 | 5/3/23 | 8/9/23 | 11/2/23 | 2/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 104 | 141 | 352 | - | - | - | 218 | 325 |
| Net Cash position 1 | - | - | - | 804 | 1,102 | 111 | - | - |
| Leverage (Debt/EBITDA) | 0.2755 x | -0.8912 x | 2.697 x | - | - | - | -0.4131 x | -1.213 x |
| Free Cash Flow 1 | 315 | 772 | 18.8 | -290 | -331 | -499 | -467 | -244 |
| ROE (net income / shareholders' equity) | 23.4% | -3.88% | -3.78% | -40.1% | -76.3% | -277% | -11.5% | -186% |
| ROA (Net income/ Total Assets) | 9.97% | -4.4% | -1.14% | -10.5% | -13.3% | -35.1% | -35% | -6.6% |
| Assets 1 | 2,949 | 10,245 | 2,536 | 2,575 | 2,760 | 1,631 | 1,440 | 4,264 |
| Book Value Per Share 2 | 11.80 | 6.020 | 5.470 | 4.030 | 2.680 | -0.3600 | -3.650 | -4.260 |
| Cash Flow per Share 2 | 2.420 | 0.2600 | 0.2200 | -1.930 | -2.150 | -2.490 | -1.840 | 0.8500 |
| Capex 1 | 30.9 | 35.1 | 12 | 15.7 | 23.8 | 23.7 | 27.9 | 29.7 |
| Capex / Sales | 2.75% | 4.82% | 1.48% | 2.68% | 3.02% | 3.8% | 3.64% | 2.69% |
| Announcement Date | 2/26/20 | 2/24/21 | 2/24/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
41.59
USD
Average target price
58.13
USD
Spread / Average Target
+39.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.79% | 6.07B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- IONS Stock
- Financials Ionis Pharmaceuticals, Inc.
